Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.41 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MLYCD | O95822 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7499182 | 1.00 | ELANE (0.41) | ELANEITGA4ITGB7ABCB1L3MBTL1 | |
| SCHEMBL4444035 | 0.86 | SIGMAR1 (0.42) | ABCB1ATMKMT2AMAPK1GPR119 | |
| SCHEMBL7504062 | 0.80 | ABCB1 (0.42) | ABCB1L3MBTL1KMT2AMAPTMAPK1 | |
| SCHEMBL3614066 | 0.80 | KEAP1 (0.41) | L3MBTL1ATMKMT2AGPR119 | |
| SCHEMBL13110173 | 0.80 | KEAP1 (0.41) | L3MBTL1ATMKMT2AGPR119 | |
| SCHEMBL3614064 | 0.80 | KEAP1 (0.41) | L3MBTL1ATMKMT2AGPR119 | |
| SCHEMBL6719418 | 0.78 | GPR119 (0.38) | ATMKMT2AMAPK1GPR119 | |
| SCHEMBL2080856 | 0.77 | HSD11B2 (0.42) | ABCB1GPR119 | |
| SCHEMBL2078385 | 0.77 | HSD11B2 (0.42) | ABCB1GPR119 | |
| SCHEMBL2078387 | 0.77 | HSD11B2 (0.42) | ABCB1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040214832-A1 | Piperazine derivative renin inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-10-28 | — | — | US | disclosed |
| WO-2004089915-A1 | PIPERAZINE DERIVATIVE RENIN INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214832-A1 | Piperazine derivative renin inhibitors | REN, ACE, AGTR2 | ELANE 369/4885ITGA4 4096/4885ITGB7 3551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.